New antibody trio takes on Hard-to-Treat lymphoma

NCT ID NCT07308132

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new drug called JNJ-95566692, a trispecific antibody designed to target lymphoma cells. It is given alone or with another drug (JNJ-87801493) to about 130 people whose B-cell non-Hodgkin lymphoma has not responded to or returned after at least two prior treatments. The main goals are to find safe doses and to watch for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JNJ-95566692 (a trispecific antibody) alone or with JNJ-87801493
What this could lead to: If it works, this could lead to a new treatment option for people with B-cell non-Hodgkin lymphoma who have run out of standard therapies.
What could go wrong: This is a very early phase 1 trial, so the main goal is safety, not effectiveness. The treatment may cause serious side effects and may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOID MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma lymphoma, non-Hodgkin, familial non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA, NON-HODGKIN

Contacts and locations

Locations

Ankara Universitesi Hastaneleri Tibbi Farmakoloji Anabilim Dali Faz 1 Klinik Arastirma Merkezi
RECRUITING

Ankara, 06620, Turkey (Türkiye)
CHU Lyon Sud
RECRUITING

Pierre-Bénite, 69495, France
CHU Pitie Salpetriere
RECRUITING

Paris, 75013, France
Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
RECRUITING

Liège, 4000, Belgium
Hopital Claude Huriez
RECRUITING

Lille, 59000, France
Hosp Univ Fund Jimenez Diaz
RECRUITING

Madrid, 28040, Spain
Hosp Univ Hm Sanchinarro
RECRUITING

Madrid, 28050, Spain
Hosp Univ Vall D Hebron
RECRUITING

Barcelona, 08035, Spain
Hosp. Clinic de Barcelona
RECRUITING

Barcelona, 8036, Spain
Hosp. Univ. 12 de Octubre
RECRUITING

Madrid, 28041, Spain
Institut Universitaire du Cancer Toulouse Oncopole
RECRUITING

Toulouse, 31100, France
Koc Universitesi Hastanesi Faz 1 Klinik Arastirma Merkezi
RECRUITING

Istanbul, 34010, Turkey (Türkiye)
Macquarie University Hospital
RECRUITING

North Ryde, 2109, Australia
Memorial Antalya Hastanesi Faz 1 Klinik Arastirma Merkezi
RECRUITING

Antalya, 07025, Turkey (Türkiye)
Monash Medical Centre
RECRUITING

Clayton, 3168, Australia
Peter MacCallum Cancer Centre
RECRUITING

Melbourne, 3000, Australia
SBU Ankara Dr. Abdurrahman Yurtaslan Onkoloji Egitim ve Arastirma Hastanesi Faz 1 Merkezi
RECRUITING

Ankara, 06200, Turkey (Türkiye)
Scientia Clinical Research
RECRUITING

Randwick, 2031, Australia
UZ Antwerpen
RECRUITING

Edegem, 2650, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.